Patent intelligence · US
US 12168692
Antibodies targeting CCR2
Antibodies targeting CCR2
Patent details — US 12168692
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 17, 2024
- Expiration
- Dec 12, 2044
- Applicant
- Granite Bio AG
- Claims
- 30
- CPC classes
- A61K, A61K2039/505
Quick answer
US 12168692 (Antibodies targeting CCR2) is held by Granite Bio AG. Status: granted. Granted Dec 17, 2024. Expires Dec 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Granite Bio AG
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2039/505
More from Granite Bio AG
Related pharmaceutical patents in our USPTO index.
-
US 12357555
Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase
granted -
US 12268831
Swallowable drug delivery device and methods of drug delivery
granted -
US 12263325
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 12214019
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
granted -
US 12201721
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
granted -
US 12128133
Ingestible device with expandable enclosure
granted -
US 12077551
Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases
granted
Frequently asked questions
What is US patent 12168692?
US 12168692 (Antibodies targeting CCR2) is held by Granite Bio AG. Status: granted. Granted Dec 17, 2024. Expires Dec 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12168692?
Granite Bio AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 148 pharmaceutical patents for this assignee.
When does US 12168692 expire?
Our index shows an expiration date of Dec 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.